Israel21C is reporting that EnzySurge out of Rosh Ha’ayin, Israel is expecting to begin FDA approval process for the complete DermaStream CST system. The wound healing device is designed to be placed over a wound to provide continuous cleaning and washing away of debris and extravasated fluid. Although the device itself received FDA clearance, the bio-active chemical solution that it is supposed to work with it has yet to get a green light.
The patent pending DermaStream CST device provides the mechanism for EnzySurge’s proprietary Continuous Streaming Therapy™ (CST). CST is a modality based on continuously streaming of fresh therapeutic solutions to the wound bed while removing exudates by vacuum assisted drainage throughout the treatment cycle. The combination of the DermaStream CSTdesign and the CST action produces negative pressure above the wound without the need for external equipment.
DermaStream is designed to ensure ongoing, uniform flow of fresh solutions over the entire wound bed The use of therapeutic solutions allows for a broad wound management platform DermaStreamCST vacuum assisted drainage continuously removes exudate and infectious material from the wound environment. Gravity-induced negative pressure removes exudates including removal of loose necrotic burden DermaStream CST is a disposable, single patient use device. It is designed to provide negative pressure above the wound bed without expensive external equipment.
Demo video of the DermaStream CST:
Product page: DermaStream CST …
More about EnzySurge’s technology from Israel21C…
Flashback: DermaStream Chronic Wound Treatment Technology
